|
|
Prolia™
Prolia is an injectable treatment for postmenopausal women with osteoporosis who are at high risk for fractures. Prolia is an every six month 60 mg subcutaneous injection administered by a health care professional. more detail |
|
|
|
Vimovo™
VIMOVO is indicated for the relief of signs and symptoms of osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis and to decrease the risk of developing gastric ulcers in patients at risk of developing NSAID associated gastric ulcers.more detail |
|
|
|
Zortress®
Zortress® (everolimus) is an oral tablets for the prevention of rejection of kidney transplants in adult patients at low-to-moderate immunologic risk.more detail |
|
|
|
Xifaxan®
Xifaxan® (rifaximin) Tablets are indicated for the treatment of patients (≥12 years of age) with travelers’ diarrhea caused by noninvasive strains of Escherichia coli. more detail |
|
|
|
MENVEO®
Menveo is a vaccine indicated for active immunization to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y and W-135. Menveo is approved for use in persons 11 to 55 years of age.more detail |
|